Cassava Sciences Inc (SAVA)

[declaes]

"Pain Therapeutics recently met with the U.S. Food and Drug Administration (FDA) regarding REMOXY ER (oxycodone extended-release capsules). During this meeting, the FDA and the Company reached agreement on a roadmap to resubmit the New Drug Application (NDA) for REMOXY ER. Details of this meeting, including timelines and additional data to be developed, will be disclosed after minutes of the meeting are issued, which may take up to three weeks."

The FDA AND THE COMPANY REACHED AGREEMENT... they havn't yet recieved the lettre from the FDA. Only then they can pr it. But in the Q19 you can see they need less money in Q1 and Q2 than they first told.